Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Centrus Contract Win

3 Dec 2012 07:00

RNS Number : 5017S
Instem plc
03 December 2012
 



03 December 2012

Embargoed for 07:00

 

Instem plc

("Instem", the "Company" or the "Group")

 

Centrus Contract Win with Top 10 Pharma

 

Leading Global Biopharmaceutical Company Purchases Instem's Centrus Software to Convert, Create and Share Research Study Data

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces today that it has signed a contract with one of the world's largest biopharmaceutical organisations. The customer has purchased multiple modules of the Centrus software suite supporting the Standard for Exchange of Nonclinical Data (SEND). This six-figure US Dollar order is the most comprehensive suite of Centrus modules purchased to date.

 

Instem's software will be used to reduce time and effort by translating study data to controlled terminology and automatically checking against SEND guidelines to ensure compliance. Additionally it includes the capability for the management, secure storage and sharing of SEND datasets with external partners.

 

The SEND standard, named by the US Food & Drug Administration ("FDA") as the preferred standard for electronic study submissions, is expected to revolutionise the process for both pharmaceutical companies and regulators. Currently, FDA reviewers receive paper or electronic paper submissions, which require time-consuming manual data input. The SEND format enables electronic submissions of nonclinical data, thereby improving efficiency as well as data quality, accessibility and predictability.

 

Instem has been an industry leader in SEND since 2004, and has been an active contributing member to several committees dedicated to advancing and promoting the standard alongside the US Food & Drug Administration (FDA). The Group's leading position in this developing area was underlined in February 2012, when Instem was recognised for its outstanding contributions to SEND at the Interchange North America event organised by CDISC, the Clinical Data Interchange Standards Consortium.

 

This order is one of a number of contracts currently under negotiation which have a possibility of closure before the year end. Some of these are required to meet revenue and profit expectations for the year. Instem expects to update on trading prior to closing the financial year ending 31 December 2012.

 

Phil Reason, CEO of Instem plc, commented: "I am delighted to announce this contract with one of the largest international biopharmaceutical companies for our innovative Centrus suite. This customer is at the forefront of developing SEND for regulatory submission as well as facilitating the aggregation of internally and externally generated study data to improve early development productivity. Given our central position in the development of the SEND standard and our established global Provantis customer base, we believe future opportunities for Centrus to be significant."

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 3205 7500

Aubrey Powell

Joe Stroud

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

About Instem plc

 

Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

 

Instem has over 130 customers in North America, Europe, China, India and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories.

 

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTBMBRTMBMJBPT
Date   Source Headline
22nd Jan 200812:11 pmRNSAcquisition
22nd Jan 200812:00 pmRNSDisposal
21st Dec 20071:22 pmRNSChange of Year End
22nd Oct 20075:57 pmRNSNotification of Shares
10th Oct 20075:29 pmRNSTrading Statement
27th Sep 200712:43 pmRNSNotification of Shares
7th Sep 20071:25 pmRNSNotification of Shares
31st Aug 20075:10 pmRNSOffer Update
31st Aug 20071:53 pmRNSTotal Voting Rights
28th Aug 20074:58 pmRNSAIM Rule 26
22nd Aug 20077:00 amRNSOffer Update
20th Aug 20072:37 pmRNSInterim Results
7th Aug 20075:41 pmRNSOffer Update
7th Aug 20075:29 pmRNSHolding(s) in Company
2nd Aug 20075:43 pmRNSExercise of options
31st Jul 20074:55 pmRNSExercise of Options
27th Jul 20078:00 amRNSIssue of Equity
24th Jul 20075:09 pmRNSOffer Update
24th Jul 20072:49 pmRNSDirector/PDMR Shareholding
24th Jul 20072:47 pmRNSDirector/PDMR Shareholding
24th Jul 20072:46 pmRNSDirector/PDMR Shareholding
24th Jul 20072:45 pmRNSDirector/PDMR Shareholding
24th Jul 20072:42 pmRNSDirector/PDMR Shareholding
23rd Jul 20073:41 pmRNSHolding(s) in Company
23rd Jul 20071:30 pmRNSAGM Statement
20th Jul 200712:08 pmRNSHolding(s) in Company
10th Jul 20072:13 pmBUSRule 8.3 - International Nuclear Solutions
9th Jul 20073:03 pmBUSRule 8.3 - International Nuclear Solutions
9th Jul 200712:10 pmRNSOffer unconditional
9th Jul 20079:33 amRNSInt Nuclear Solutions
6th Jul 20073:09 pmBUSRule 8.3 - International Nuclear Solutions
5th Jul 20071:51 pmBUSRule 8.3 - International Nuclear Solutions
4th Jul 200712:38 pmBUSRule 8.3 - International Nuclear Solutions
3rd Jul 20072:25 pmBUSRule 8.3 - International Nuclear Solutions
29th Jun 20073:05 pmRNSHolding(s) in Company
28th Jun 200711:44 amRNSHolding(s) in Company
28th Jun 20079:24 amRNSRule 8.1- Intnl Nuclear Sol.
27th Jun 20073:34 pmBUSRule 8.3 - International Nuclear Solutions
25th Jun 20073:18 pmRNSRule 8.1- (Intl Nuclear Sol)
25th Jun 20079:01 amRNSHolding(s) in Company
21st Jun 20072:52 pmBUSRule 8.3 - International Nuclear Solution
21st Jun 20072:34 pmRNSRule 8.3- Int'l Nuclear Sol
20th Jun 20073:19 pmBUSRule 8.3 - INTERNATIONAL NUCLEAR SOLUTIONS
20th Jun 20071:35 pmRNSRule 8.3- Int'l Nuclear Sol.
20th Jun 200710:16 amRNSRule 8.3- Intl Nuclear Sols
20th Jun 200710:02 amRNSRule 8.1- Intl Nuclear Sol
19th Jun 20077:03 amRNSOffer for INS
15th Jun 200711:53 amRNSRule 8.3- Intnl Nuclear
12th Jun 200711:08 amRNSRule 8.3- Intnl Nuclear Sol.
29th May 20073:18 pmBUSRule 8.3 - International Nuclear Solution

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.